VANCOUVER, British Columbia / Oct 22, 2024 / Business Wire / AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:
Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.
About AbCellera Biologics Inc.
AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.
| Last Trade: | US$5.91 |
| Daily Change: | -0.26 -4.21 |
| Daily Volume: | 5,491,457 |
| Market Cap: | US$1.770B |
August 07, 2025 May 30, 2025 May 12, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
